Cell Disruption Patents: Who Leads, Where the Gaps Are 2026
Continuous Cell Disruption Patents: Filing Trends and Where Claim Space Is Still Open
23.1% of all 616 records sit with just five assignees, yet the ranked leader holds only 44 records — concentrated at the top without a dominant single owner. Filings rose from 26 in 2017 to a peak of 47 in 2020, then declined to 15 by 2021 and 5 by 2024 — a 67% drop over that three-year span. Because 2025 and 2026 are still filling in under the publication lag, treat 2024 as the last complete data point rather than reading the tail as a further slowdown.
- 1CENTELION SAS44
- 2GREENLIGHT BIOSCIENCES INC30
- 3GENENTECH INC24
- 4CORBION BIOTECH INC23
- 5MERCK & CO INC21
See the full cell disruption continuous disruption analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in continuous cell disruption?
The ranked leader in this dataset holds 44 of the 616 records in scope, with the fifth-ranked assignee at 21 and the tenth at 13. That is a real lead but far from a majority position — the top 5 combined account for only 23.1% of all records, so no single company controls the field. A freedom-to-operate review needs to look well beyond the top name.
Is patent filing in cell disruption technology growing or shrinking?
Filings peaked in 2020 at 47 and then declined sharply, falling from 15 in 2021 to 5 in 2024 — a 67% drop over that span. 2024 is the most recent year in this dataset treated as complete, since publication typically lags actual filing by around 18 months. The 2025 and 2026 figures will rise as more records publish, so they should not yet be read as continued decline.
What patent classes cover continuous cell lysis methods?
The dominant class is C12N (microorganisms and genetic engineering), covering 90.7% of the 616 records, reflecting that most claims are tied to a specific biological substrate rather than generic apparatus. C12P (fermentation) and C12M (bioreactors) each cover close to 29%, and C12Q (enzyme/DNA testing) covers 23.4%. Purely mechanical classes like B01J and B01F stay under 10%, which is worth noting if you are trying to claim disruption hardware independent of the material being processed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell Disruption Continuous Disruption covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.